Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.50 |
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7085256 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL17540757 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2733841 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL25300764 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2734708 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL25299017 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL3344018 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL1286332 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL16721005 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL9754723 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190076354-A1 | OPHTHALMIC PREPARATIONS | SGN NANOPHARMA INC. (US) | 2019-03-14 | — | — | US | claimed |
| US-20190070106-A1 | OPHTHALMIC PREPARATIONS | SGN NANOPHARMA INC. (US) | 2019-03-07 | — | — | US | claimed |
| EP-2240157-A1 | OPHTHALMIC PREPARATIONS | Novavax, Inc. (US) | 2010-10-20 | — | — | EP | claimed |
| US-20100226932-A1 | Adjuvant and Vaccine Compositions | NOVAVAX, INC. (US) | 2010-09-09 | — | — | US | claimed |
| US-20100143420-A1 | MULTI-PHASIC PHARMACEUTICAL FORMULATIONS OF POORLY WATER-SOLUBLE DRUGS FOR REDUCED FED/FASTED VARIABILITY AND IMPROVED ORAL BIOAVAILABILITY | NOVAVAX, INC | 2010-06-10 | — | — | US | claimed |
| US-20100143481-A1 | METHOD OF PREPARING SOLID DOSAGE FORMS OF MULTI-PHASIC PHARMACEUTICAL COMPOSITIONS | NOVAVAX, INC. | 2010-06-10 | — | — | US | claimed |
| WO-2009091894-A1 | OPHTHALMIC PREPARATIONS | NOVAVAX, INC. (US) | 2009-07-23 | — | — | WO | claimed |
| EP-2079450-A2 | METHOD OF PREPARING SOLID DOSAGE FORMS OF MULTI-PHASIC PHARMACEUTICAL COMPOSITIONS | Novavax, INC. (US) | 2009-07-22 | — | — | EP | claimed |
| US-20090162442-A1 | MULTI-PHASIC, NANO-STRUCTURED COMPOSITIONS CONTAINING A COMBINATION OF A FIBRATE AND A STATIN | NOVAVAX, INC. | 2009-06-25 | — | — | US | claimed |
| EP-2051702-A1 | MULTI-PHASIC PHARMACEUTICAL FORMULATIONS OF POORLY WATER-SOLUBLE DRUGS FOR REDUCED FED/FASTED VARIABILITY AND IMPROVED ORAL BIOAVAILABILITY | Novavax, Inc. (US) | 2009-04-29 | — | — | EP | claimed |
| EP-2001439-A2 | NANOEMULSIONS OF POORLY SOLUBLE PHARMACEUTICAL ACTIVE INGREDIENTS AND METHODS OF MAKING THE SAME | NOVAVAX, INC. (US) | 2008-12-17 | — | — | EP | claimed |
| US-20080299206-A1 | Ophthalmic preparations | NOVAVAX, INC. | 2008-12-04 | — | — | US | claimed |
| EP-1988918-A2 | ADJUVANT AND VACCINE COMPOSITIONS | Novavax, Inc. (US) | 2008-11-12 | — | — | EP | claimed |
| WO-2008091855-A1 | MULTI-PHASIC PHARMACEUTICAL FORMULATIONS OF POORLY WATER-SOLUBLE DRUGS FOR REDUCED FED/FASTED VARIABILITY AND IMPROVED ORAL BIOAVAILABILITY | NOVAVAX, INC. (US) | 2008-07-31 | — | — | WO | claimed |
| US-20080139513-A1 | TRANSDERMAL DELIVER OF ACTIVE AGENTS | NOVAVAX, INC. | 2008-06-12 | — | — | US | claimed |
| WO-2008063910-A2 | METHOD OF PREPARING SOLID DOSAGE FORMS OF MULTI-PHASIC PHARMACEUTICAL COMPOSITIONS | NOVAVAX, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| US-20070264349-A1 | Nano-structured compositions and methods of making and using the same | NOVAVAX, INC. | 2007-11-15 | — | — | US | claimed |
| WO-2007123790-A1 | NANOSTRUCTURED COMPOSITIONS HAVING ANTIBACTERIAL, ANTI-FUNGAL, ANTI-YEAST, AND/OR ANTI-VIRAL PROPERTIES | NOVAVAX, INC. (US) | 2007-11-01 | — | — | WO | claimed |
| WO-2007103294-A2 | NANOEMULSIONS OF POORLY SOLUBLE PHARMACEUTICAL ACTIVE INGREDIENTS AND METHODS OF MAKING THE SAME | NOVAVAX, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| WO-2007098186-A2 | ADJUVANT AND VACCINE COMPOSITIONS | NOVAVAX, INC. (US) | 2007-08-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139513-A1 | TRANSDERMAL DELIVER OF ACTIVE AGENTS | TTPA, TSLP, TMSB10 | FAAH 922/4885CES1 2769/4885CES2 756/4885 |
| US-20190070106-A1 | OPHTHALMIC PREPARATIONS | EYA3, TSLP, IL5 | FAAH 1798/4885CES1 3304/4885CES2 4620/4885 |
| US-20070264349-A1 | Nano-structured compositions and methods of making and using the same | ABCG2, SI, LIPA | FAAH 3535/4885CES1 1015/4885CES2 1769/4885 |
| US-20080299206-A1 | Ophthalmic preparations | EYA3, TSLP, IL5 | FAAH 1798/4885CES1 3304/4885CES2 4620/4885 |
| US-20190076354-A1 | OPHTHALMIC PREPARATIONS | EYA3, TSLP, IL5 | FAAH 1798/4885CES1 3304/4885CES2 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.